INNVMEDIUM SIGNALFINANCIAL10-K

INNV showed revenue growth and reduced interest expense but widening losses and deteriorating profitability despite serving more PACE participants.

The company expanded its PACE participant base by over 10% to 7,740 participants while growing revenue, indicating successful scale expansion in its core market. However, the widening net losses and declining operating performance suggest operational efficiency challenges that are offsetting the benefits of growth, which could pressure margins and cash flow going forward.

Comparing 2025-09-09 vs 2024-09-10View on EDGAR →
FINANCIAL ANALYSIS

INNV delivered solid top-line growth with revenue increasing 11.8% to $853.7M and gross profit expanding 16.3% to $153.6M, while interest expense declined substantially from $16.8M to $2.5M. However, operating losses widened meaningfully to $29.8M and net losses increased to $30.3M, indicating that operating expense growth outpaced the gross profit gains. The balance sheet shows mixed signals with improved cash position but reduced stockholders' equity and higher current liabilities.

FINANCIAL STATEMENT CHANGES
Interest Expense
P&L
-85%
$16.8M→$2.5M

Interest expense declined — debt repayment or refinancing at lower rates improving earnings quality.

Net Income
P&L
-42.1%
-$21.3M→-$30.3M

Net income declined 42.1% — review whether driven by operations, interest costs, or non-recurring items.

Operating Income
P&L
-28.4%
-$23.2M→-$29.8M

Operating profitability softening — costs rising faster than revenue, watch for margin recovery plan.

Accounts Receivable
Balance Sheet
-24.4%
$48.1M→$36.4M

Receivables declined — improved collection efficiency or conservative revenue recognition.

Capital Expenditure
Cash Flow
-20.9%
$7.9M→$6.3M

Capex reduced 20.9% — investment cycle winding down or capital discipline; may improve near-term free cash flow.

Current Liabilities
Balance Sheet
+18.9%
$138.6M→$164.8M

Current liabilities rose 18.9% — increased short-term obligations, watch current ratio.

Gross Profit
P&L
+16.3%
$132.1M→$153.6M

Gross profit expanding — improving pricing power or product mix shift toward higher-margin offerings.

Stockholders Equity
Balance Sheet
-12.7%
$269.3M→$235.0M

Equity decreased 12.7% — buybacks or losses reducing book value, monitor solvency ratios.

Cash & Equivalents
Balance Sheet
+12.6%
$56.9M→$64.1M

Cash grew 12.6% — improving liquidity position supports investment and shareholder returns.

Revenue
P&L
+11.8%
$763.9M→$853.7M

Revenue growing 11.8% — solid top-line momentum, watch margins for quality of growth.

LANGUAGE CHANGES
NEW — 2025-09-09
PRIOR — 2024-09-10
ADDED
As of September 2, 2025, there were 135,637,975 shares of the registrant s common stock outstanding.
Changes in and Disagreements with Accountants on Accounting and Financial Disclosure 100 Item 9A.
Healthcare reform, the regulation of the corporate practice of medicine and the Health Information Technology for Economic and Clinical Health Act of 2009 (the HITECH Act ), and their implementing regulations (collectively, HIPAA ), and other privacy laws and regulations in the healthcare industry; our status as a controlled company ; the volatility of our stock price; our ability to comply with the continued listing requirements of Nasdaq; and other factors disclosed in the section entitled Risk Factors and elsewhere in this Annual Report.
PACE As of June 30, 2025, the Company served approximately 7,740 PACE participants, making it the largest PACE provider in the United States (the U.S.
In addition to reducing spend, we also focus on ensuring our participants are satisfied with the services delivered and frequently evaluate benchmarks and survey methodologies to measure their satisfaction.
Our participant satisfaction is currently measured through a Net Promoter Score ( NPS ).
Based on quarterly surveys to measure emerging sentiment within a subset of our participants nationally, our average NPS was 45.
As part of our quarterly surveys, each year, we conduct an I-SAT survey ( Integrated Satisfaction Measurement for PACE ) to measure NPS across a national sample of our participants.
In fiscal year 2025, our I-SAT NPS score was 56, which compares favorably to a national PACE program average of 55.
According to data from the Office of the Actuary of CMS, healthcare spending in the United States grew at approximately 6% per year from 2018 to 2023, and in 2023 represented $4.9 trillion of annual spend, or 17.6% of U.S.
REMOVED
As of September 9, 2024, there were 135,620,541 shares of the registrant s common stock outstanding.
Changes in and Disagreements w ith Accountants on Accounting and Financial Disclosure 97 Item 9A.
PACE As of June 30, 2024, the Company served approximately 7,020 PACE participants, making it the largest PACE provider in the United States (the U.S.
In addition to reducing spend, we also focus on ensuring our participants are satisfied with the services delivered.
Our participant satisfaction is administered quarterly and is measured through a Net Promoter Score ( NPS ).
Based on surveys of our participants administered by a third-party vendor in FY24, our average FY24 NPS was 46.
According to data from the Office of the Actuary of CMS, healthcare spending in the United States grew at approximately 5% per year from 2017 to 2022, and in 2022 represented $4.5 trillion of annual spend, or 17.3% of U.S.
We believe government healthcare spend is higher for the dual-eligible population, who typically suffer from multiple chronic conditions and require long-term services and supports.
We believe Medicare and Medicaid spend on average three times more per capita on a dual-eligible senior than a Medicare-only senior.
A 2019 study, published in the Journal of the American Medical Association, estimated that approximately 25% of all annual healthcare spending is for unnecessary services, excessive administrative costs, fraud and other inefficiencies creating waste.
MORE FINANCIAL SIGNALS
CRMHIGHSalesforce significantly increased debt by 71% to $14.4B while simultaneously ac...
2026-03-02
UNHHIGHUNH's operating income plummeted 41% despite 12% revenue growth, indicating seve...
2026-03-02
PFEHIGHPfizer achieved a dramatic 87.3% reduction in total debt from $31.4B to $4.0B, r...
2026-02-26
GILDHIGHGILD dramatically increased R&D spending by 81.5% to $9.1B while introducing new...
2026-02-24
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →